Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors

Trial Profile

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Navitoclax (Primary) ; Dabrafenib; Trametinib
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 Jun 2016 Planned number of patients changed from 70 to 68.
    • 30 Jun 2016 Planned number of patients changed from 70 to 68.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top